COVID-19 Pandemic

Mergers And Acquisitions Will Drive Biotech Post-Vaccine – And This ETF Could Benefit

“Once a tried-and-true [COVID-19] vaccine is developed and subsequently incorporated as standard fare in medical practice, one driver of biotech will be mergers and acquisitions,” advises the author of today’s article. He proceeds to highlight an ETF that could benefit from this particular driving force – a fund that has generated a 30% return this year. For more, CLICK HERE.

A ‘Dream’ Cannabis Opportunity?

An estimated 70 million Americans suffer from insomnia – and that number is undoubtedly climbing as the country deals with the stress and anxiety associated with the COVID-19 pandemic. While many for whom sleep proves to be elusive turn to prescription medications and over-the-counter sleep aids, there’s evidence that adults are increasingly turning to cannabis to help promote sleep –…